Lung cancer

Young Investigators awarded $200k to study innovative new ways to engage the body’s immune system to fight lung cancer

Friday, January 15, 2021 - 10:03am

Los Angeles, CA, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Two new $200,000 grant-funded studies supported by the Lung Cancer Foundation of America, the International Lung Cancer Foundation, and generously funded in part by Bristol-Myers Squibb , are investigating ways to harness the bodys powerful immune system to better treat lung cancer.

Key Points: 
  • Los Angeles, CA, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Two new $200,000 grant-funded studies supported by the Lung Cancer Foundation of America, the International Lung Cancer Foundation, and generously funded in part by Bristol-Myers Squibb , are investigating ways to harness the bodys powerful immune system to better treat lung cancer.
  • His research focuses on ALK+ lung cancer, which predominantly affects younger patients and those without significant smoking exposure.
  • The International Lung Cancer Foundation aims to accelerate the pace of thoracic malignancy research, to inspire researchers to focus their careers on lung cancer, and to reduce the worldwide lung cancer mortality rate.Established in 2014, the ILCF has provided over $6 million towards global lung cancer research.
  • Lung Cancer Foundation of America is leading the fight against lung cancer through funding innovative and transformative lung cancer research.

January Radon Action Month: Better Understanding...Better Results

Thursday, January 14, 2021 - 6:00am

The parallel affects between COVID-19 and radon really bring to light how unseen environmental hazards can affect human life.

Key Points: 
  • The parallel affects between COVID-19 and radon really bring to light how unseen environmental hazards can affect human life.
  • Being diagnosed with lung cancer is a drastic way to discover the danger of radioactive radon gas exposure.
  • If test results are revealed to be elevated, always use a certified radon professional mitigator to install a system that will lower the level of radon.
  • A list of certified professionals can be found through https://www.epa.gov/indoor-air-quality-iaq/how-can-you-find-qualified-ra...
    Increase your knowledge of radon at Citizens for Radioactive Radon Reduction.

China National Medical Products Administration Approves Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer

Thursday, January 14, 2021 - 4:00am

This is the third approval in China for tislelizumab, and its first in a lung cancer indication.

Key Points: 
  • This is the third approval in China for tislelizumab, and its first in a lung cancer indication.
  • Tislelizumab is being investigated in a broad clinical program, including five Phase 3 trials in lung cancer indications.
  • We are grateful to have a new treatment available in the front-line setting for patients with advanced squamous non-small cell lung cancer, said Jie Wang, M.D., Ph.D., National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College.
  • The China National Medical Products Administration (NMPA) has granted tislelizumab full approval for first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC) in combination with chemotherapy.

Global Non-Small Cell Lung Cancer Drug Forecast and Market Analysis 2019-2020 & 2029 - 29 Late-stage Pipeline Agents are Going to Enter the NSCLC Market

Wednesday, January 13, 2021 - 8:15pm

DUBLIN, Jan. 13, 2021 /PRNewswire/ -- The "Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 13, 2021 /PRNewswire/ -- The "Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.
  • Non-small cell lung cancer (NSCLC) is currently the most common cancer in the world and is the leading cause of cancer mortality in men and women.
  • 29 late-stage pipeline agents are going to enter the NSCLC market from 2019 onwards.
  • Topline NSCLC market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.

AstraZeneca to Showcase Transformative Data Across Diverse Pipeline at World Conference on Lung Cancer

Wednesday, January 13, 2021 - 2:00pm

1 39 abstracts at WCLC 2020 will feature AstraZeneca medicines and pipeline molecules, of which 24 are company-sponsored or supported.

Key Points: 
  • 1 39 abstracts at WCLC 2020 will feature AstraZeneca medicines and pipeline molecules, of which 24 are company-sponsored or supported.
  • Severe, life-threatening, or fatal interstitial lung disease (ILD), including pneumonitis, can occur in patients treated with ENHERTU.
  • In clinical studies, of the 234 patients with unresectable or metastatic HER2-positive breast cancer treated with ENHERTU, ILD occurred in 9% of patients.
  • EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumor tissue and cytology samples.

Genprex Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer

Wednesday, January 13, 2021 - 2:00pm

This production provides supply of REQORSA for our two upcoming Acclaim clinical trials and advances our mission to develop innovative new treatments for non-small cell lung cancer patients greatly in need of effective therapy options.

Key Points: 
  • This production provides supply of REQORSA for our two upcoming Acclaim clinical trials and advances our mission to develop innovative new treatments for non-small cell lung cancer patients greatly in need of effective therapy options.
  • The Company also reported the completion of the manufacturing scale-up for the clinical-grade production of REQORSA , subject to final testing that was underway.
  • From there, REQORSA supply will be delivered to the clinical trial sites pending FDA clearance to commence the clinical trials.
  • The Companys lead product candidate, REQORSA (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC).

Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands and Japan to Enhance Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the eNRGy Clinical Trial

Tuesday, January 12, 2021 - 9:01pm

National Cancer Center (NCC) Japan has agreed to provide RNA sequencing, funded in part by Merus, for eligible patients with pancreatic adenocarcinoma and patients with NSCLC to identify NRG1 fusions.

Key Points: 
  • National Cancer Center (NCC) Japan has agreed to provide RNA sequencing, funded in part by Merus, for eligible patients with pancreatic adenocarcinoma and patients with NSCLC to identify NRG1 fusions.
  • NCC Japan, established in 1962, is a leading medical institution in cancer treatment and research in Japan.
  • NCCHE, established in 1992, is one of the leading specialized cancer hospitals in Japan, treating over 9,000 new patients each year.
  • The eNRGy trial consists of three cohorts: NRG1+ pancreatic cancer; NRG1+ non-small cell lung cancer; and NRG1+ other solid tumors.

Global Non-Small Cell Lung Cancer Drug Forecast and Market Analysis to 2029 - ResearchAndMarkets.com

Tuesday, January 12, 2021 - 12:47pm

The "Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.
  • Non-small cell lung cancer (NSCLC) is currently the most common cancer in the world and is the leading cause of cancer mortality in men and women.
  • Of total lung cancer incident cases, approximately 85% are the NSCLC subtype.
  • Since the last global market forecast (2015-2025), there have been significant changes in the treatment of patients with advanced disease, particularly in the metastatic setting.

Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities

Tuesday, January 12, 2021 - 8:30am

Lugano, Switzerland, January 12, 2021 Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, today announces the first patient has been dosed in a Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities.

Key Points: 
  • Lugano, Switzerland, January 12, 2021 Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, today announces the first patient has been dosed in a Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities.
  • In 2017, Helsinn and Taiho signed a global co-development and commercialization agreement for TAS0953/HM06.
  • Riccardo Braglia, Helsinn Group Vice Chairman and CEO commented: "We are very pleased to have dosed the first patient in this Phase 1/2 study with TAS0953/HM06.
  • TAS0953/HM06 is an oral RET inhibitor in development for advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) and other tumors which express RET gene abnormalities.

Pivotal phase III clinical trial IND submission of the original innovative anticancer drug Chiauranib for the treatment of small cell lung cancer was accepted by the Center of Drug Evaluation of the NMPA.

Monday, January 11, 2021 - 3:03am

The submission has been accepted by the Center of Drug Evaluation of the NMPA.

Key Points: 
  • The submission has been accepted by the Center of Drug Evaluation of the NMPA.
  • The population of SCLC patients account for about 15-20% of all lung cancer patients.
  • For the moment, the main clinical treatment methods of SCLC are radiotherapy and chemotherapy, which may only have short-term effect, and the disease is easy to relapse.
  • This also lays a good start for the further development of Chiauranib, which is the third original innovative drug discovered and developed by Chipscreen.